31 results about "Sustained release pellets" patented technology

The invention provides a sustained-release pellet containing gamma-aminobutyric acid, the sustained-release pellet comprises a pellet core and a coating layer wrapping the pellet core, the pellet core contains a physiologically active substance, and the physiologically active substance is gamma-aminobutyric acid; the pellet core comprises the following components in parts by weight: 15-40 parts of gamma-aminobutyric acid, 30-55 parts of a filling agent, 1-30 parts of a lubricating agent and 0.5-5 parts of an anti-caking agent; the filling agent comprises at least one of microcrystalline cellulose, powdery cellulose, starch and derivatives thereof, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, sugar or sugar alcohol and fruit and vegetable powder; the lubricant comprises at least one of talcum powder, magnesium stearate, stearic acid, glycerol and leucine; the anti-caking agent comprises at least one of magnesium carbonate, tricalcium phosphate, calcium hydrophosphate and silicon dioxide.

The invention discloses a multi-system function regeneration factor composition as well as a preparation method and application thereof. The multi-system function regeneration factor composition is prepared from the following components in parts by mass: 0.8 to 2.4 parts of melatonin, 84 to 126 parts of nicotinamide ribose and 42 to 84 parts of resveratrol. According to the multi-system functional regeneration factor composition disclosed by the invention, through scientific proportioning and synergistic effect of melatonin, nicotinamide ribose and resveratrol, the functions of stem cells are strongly activated, proliferation of the stem cells is remarkably promoted, the stemness maintaining capability of the stem cells is improved, osteogenesis and adipogenesis differentiation potential is enhanced, and the regeneration effect of the stem cells is improved. Meanwhile, an NAD < + > metabolic pathway is activated so as to strengthen cell energy and anti-aging capability. The capsule adopts the design of combining quick-release pellets and sustained-release pellets, the quick-release part can quickly release melatonin, the local drug concentration can be increased in a short time, and stem cell activation signals can be quickly started; and the sustained release part slowly releases nicotinamide ribose and resveratrol to maintain the long-acting stability of the drug concentration, so that the effect taking speed is ensured, the action time is prolonged, and the bioavailability is greatly improved.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

The application discloses a slow-release micro-pellet containing gamma-aminobutyric acid and a preparation method and application thereof. Gamma-aminobutyric acid is wrapped in a mucosal adhesion material in a fluidized bed to form a micro-pellet, and the micro-pellet is dispersed in an aqueous alginate solution to form a micro-pellet with a size of about 1-10 mm through calcium ion cross-linking. The slow-release micro-pellet overcomes the shortcomings of a product without cross-linked alginate, such as poor slow-release effect and easy burst release of active ingredients, has a biological membrane adhesion property, can realize stable release of GABA in a small intestine for at least 8 hours, presents obvious slow-release characteristics in a beagle dog in vivo, significantly delays a peak time, significantly reduces a peak concentration, significantly prolongs an elimination half-life, keeps a blood drug concentration stable and small fluctuation, and significantly improves a relative oral bioavailability. The application has the advantages of a soft and elastic texture after water absorption, chewability, and flexible and various taking modes. In addition, the application has a simple preparation process and can realize industrial production.

The invention provides a nicotine sustained-release capsule, the nicotine sustained-release capsule comprises a content, the content comprises a sustained-release pellet, the sustained-release pellet comprises an active core, a first coating layer and a second coating layer which are sequentially arranged from inside to outside, the active core comprises at least one of nicotine or a nicotine derivative, the first coating layer comprises a first adhesive, and the second coating layer comprises a second adhesive. The second coating layer comprises a second adhesive, and the second coating layer is an enteric coating; through the design of the nicotine sustained-release capsule dosage form, the drug release rate can be delayed, the stable blood concentration can be maintained, the drug effect duration can be prolonged, the smoking process of'low-dose sustained release 'can be simulated, and the emotion and physiological reaction in the smoking cessation process can be improved; in addition, the design of the double-layer coating is also helpful for stabilizing the fluctuation of the blood concentration, and a safer, more continuous and milder nicotine release process is realized.

The application belongs to the technical field of pharmaceutical preparations, and discloses a soft capsule preparation containing alfacalcidol and a preparation method thereof. The soft capsule preparation comprises a soft capsule shell and content filled in the soft capsule shell, and the content is composed of a drug-containing oil phase and alfacalcidol sustained-release pellets dispersed in the oil phase. The drug-containing oil phase comprises immediate-release alfacalcidol dissolved in an oily base. The sustained-release pellets comprise a blank pellet core, a drug-loaded layer and a separation layer, and the separation layer comprises a combined coating material of Eudragit RS30D and Eudragit RL30D. After oral administration, the alfacalcidol in the oil phase is rapidly released to achieve immediate effect, and the alfacalcidol in the sustained-release pellets is slowly released to maintain the steady state of blood drug concentration. The soft capsule preparation of the application realizes the dual-phase drug release behavior of immediate release and sustained release in the same soft capsule, so that the blood drug concentration is smooth and controllable within 24 hours, the steady state of blood drug concentration is maintained, the frequency of drug administration is reduced, and the risk of side effects such as hypercalcemia is reduced.

The invention discloses budesonide enteric-coated sustained-release pellets and a preparation method thereof, and belongs to the technical field of biological medicines. The budesonide enteric-coated and sustained-release pellet sequentially comprises a medicine-containing pellet core, a sustained-release layer and an enteric-coated layer from inside to outside, the drug-containing pill core comprises budesonide, a filler, an adhesive, an acidic agent and a lubricant; the sustained-release layer comprises the following components: a retardant, a plasticizer and an anti-sticking agent; the enteric-coated layer comprises the following components: an enteric-coated material, a plasticizer and an anti-sticking agent. The budesonide enteric-coated sustained-release pellet is prepared by the following steps: preparing budesonide and auxiliary materials into a drug-containing pellet core through an extrusion rolling process, and then coating the drug-containing pellet core with a sustained-release layer and an enteric-coated layer in sequence through a fluidized bed coating, thereby obtaining the budesonide enteric-coated sustained-release pellet. The budesonide enteric-coated and sustained-release pellet cannot be released and absorbed in the stomach, the effect gradually starts after the budesonide enteric-coated and sustained-release pellet reaches the intestinal tract, and the budesonide enteric-coated and sustained-release pellet keeps a proper concentration level in in-vivo blood, so that targeted continuous treatment of inflammatory intestinal diseases is facilitated.

The invention relates to a high-content 5-aminolevulinic acid sustained-release pellet, which comprises the following components: 5-aminolevulinic acid phosphate; microcrystalline cellulose (MCC PH-102); hydroxypropyl cellulose (HPC-SL); 2-5% of pregelatinized starch; sodium carboxymethyl starch (CMS-Na); sucrose; the drug loading capacity is 60 + / -2%, and the bulk density is 0.65-0.75 g / cm < 3 >.

The invention discloses an icariin enteric-coated sustained-release pellet and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparations, and the pellet sequentially comprises a drug-containing pellet core, a sustained-release coating layer and an enteric coating layer from inside to outside. The pellet core contains icariin, microcrystalline cellulose, an adhesive, a disintegrating agent and an antioxidant; the sustained-release coating layer takes ethyl cellulose as a sustained-release material; the enteric coating layer takes acrylic resin and sodium alginate as dual pH response materials, the 2-hour release rate of the pellet in a hydrochloric acid solution with the pH value of 1.0 is less than 10%, the pellet presents near-zero-order release kinetics in a buffer solution with the pH value of 6.8 within 12 hours, the problems that icariin is degraded in gastric acid, the bioavailability is low and the half-life period is short are solved, the icariin can be administrated twice a day, and the bioavailability is high. The traditional Chinese medicine composition is used for treating kidney-yang deficiency type impotence, premature ejaculation and infertility.

The invention belongs to the technical field of pharmaceutical preparations, and provides a probucol sustained-release capsule for reducing the blood fat level and a preparation method thereof, and the probucol sustained-release capsule is prepared by filling a capsule shell with sustained-release pellets, the sustained-release pellet comprises a blank pellet core, a medicine carrying layer, an isolating layer and a sustained-release layer from inside to outside, wherein the medicine carrying layer comprises probucol and an adhesive in a mass ratio of (200-250): (8-12); the slow-release layer is prepared from eudragit RL PO, a plasticizer, a pore-foaming agent and an anti-sticking agent according to the mass ratio of (250 to 300) to (20 to 25) to (20 to 22) to (10 to 18); the pore-foaming agent is prepared from polyethylene glycol 400 and PVP K25 in a mass ratio of (8-12): (3-5). The probucol sustained-release capsule provided by the invention not only has an excellent sustained-release effect, but also enables drug absorption to be less affected by gastric emptying, reduces stimulation to gastrointestinal tracts, and can improve patient compliance.

The invention belongs to the technical field of pharmacy, and particularly relates to a rhizoma phragmitis sustained release preparation for hyperuricemia and a preparation method of the rhizoma phragmitis sustained release preparation. The reed rhizome sustained release preparation for hyperuricemia is prepared from the following raw materials in parts by weight: 80 to 100 parts of reed rhizome extract, 160 to 200 parts of functionalized reed rhizome powder, 0.01 to 0.1 part of freeze-dried powder, 40 to 65 parts of quercetin and 30 to 50 parts of acrylic resin, the rhizoma phragmitis extract and quercetin cooperate to comprehensively regulate uric acid metabolism; due to the introduction of the freeze-dried powder, real-time visual monitoring of in-vivo drug distribution and drug release progress is realized, and the targeting affinity of the preparation with intestinal mucosa and joint parts can be improved, so that the blood uric acid level quickly tends to be stable and is maintained for a long time; after the colon target positioning sustained-release pellet and the quercetin quick-release pellet are mixed, the quick-release pellet can be quickly disintegrated and release quercetin to realize quick acid control, and the sustained-release pellet can accurately deliver drugs in the colon and continuously release active ingredients to realize long-acting acid stabilization.

The invention discloses a metoprolol succinate sustained-release tablet and a preparation method thereof. The tablet comprises a gastric-soluble film coating, a blank filling auxiliary material and a drug-containing sustained-release pellet, the blank filling auxiliary material comprises the following components in parts by weight: 20-40 parts of microcrystalline cellulose, 0.5-2 parts of magnesium stearate and 0.3-1 part of silicon dioxide; the drug-containing sustained-release pellet is composed of a blank pellet core, a drug layer and a sustained-release coating layer, the blank pellet core comprises 10-25 parts of a microcrystalline cellulose pellet core, and the drug layer comprises 25-100 parts of metoprolol succinate, 5-20 parts of lactose and 1-5 parts of povidone K30; the slow-release coating layer is prepared from 3 to 10 parts of ethyl cellulose; by screening the diameter of the pellet and the viscosity of ethyl cellulose, the preparation can realize slow release of drugs, and is low in content of related substances and total impurities, stable in quality and suitable for industrial production.

The invention discloses a collagen composite soft capsule with a three-layer structure as well as a preparation method and application of the collagen composite soft capsule, and belongs to the technical field of composite sustained-release capsules. The capsule contains an outer collagen peptide-gelatin composite rubber layer, a middle Pickering emulsion layer and an inner sustained-release pellet. A compact network is formed on the outer layer under the action of molecules, so that the mechanical strength and the biocompatibility are improved; the middle layer stably loads active ingredients; and the inner-layer sustained-release pellet fixes collagen peptide and integrates various components, so that controlled release is realized. During preparation, a three-layer structure is constructed step by step, physical mixing avoids damage to activity, step-by-step injection keeps each layer independent, and sealing does not need an additional adhesive. The process enhances the strength of the capsule skin, ensures the structural stability, accurately controls the sustained-release structure of the pellet, and improves the gastric acid tolerance and active ingredient stability of the capsule.

The invention relates to a pharmaceutical composition for oral administration. The pharmaceutical composition comprises: a) immediate release particles comprising i. An active ingredient selected from the group consisting of valproic acid, semi-sodium valproate, sodium valproate and magnesium valproate, and ii. A filler, b) sustained release pellets comprising: i. A pellet core comprising (1) an active ingredient selected from the group consisting of valproic acid, semi-sodium valproate, sodium valproate and magnesium valproate, and (2) a filler, ii. A sub-coating disposed on the pellet core, the content of the sub-coating layer is 10-20 wt% based on the weight of the pellet core and the sub-coating layer comprises a film-forming agent, and iii. A slow-release coating layer disposed on the sub-coating layer, the content of the slow-release coating layer is 25-100 wt% based on the weight of the pellet core coated with the sub-coating layer and the slow-release coating layer comprises a film-forming agent, and the content of the slow-release coating layer is 25-100 wt% based on the weight of the pellet core coated with the sub-coating layer. Wherein the amount of the active ingredients in the quick-release particles accounts for 70-80 wt% of the total weight of the active ingredients in the pharmaceutical composition, and the amount of the active ingredients in the slow-release pellets accounts for 20-30 wt% of the total weight of the active ingredients in the pharmaceutical composition. In further aspects, the present invention relates to methods of preparing pharmaceutical compositions and pharmaceutical compositions for use in methods of pre-treating cancer.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and particularly discloses a traditional Chinese medicine composition for treating rheumatoid arthritis and a preparation method thereof. The composition is prepared from tripterygium wilfordii, caulis sinomenii, radix paeoniae alba, liquorice, radix aconiti preparata, pseudo-ginseng, radix clematidis, radix achyranthis bidentatae, gentiana macrophylla and herba pyrolae, and is composed of a quick-release pellet, an enteric-coated sustained-release pellet and a delayed sustained-release pellet. The preparation method comprises the following steps: grouping the raw materials according to efficacy, and respectively performing independent directional extraction and refining to obtain an intermediate; part of the intermediates are subjected to a composite reaction and then used for preparing quick-release pellets; the rest intermediates are respectively used for preparing enteric sustained-release pellets and delayed sustained-release pellets; and finally, mixing the three pellets. According to the composition disclosed by the invention, through a multi-unit sequential controlled release design, sequential treatment on different pathological links of rheumatoid arthritis is realized. In addition, the preparation method disclosed by the invention aims to improve the extraction pertinence of each functional component and the overall quality controllability of the preparation through the combination of functional grouping and an orientation process.

The invention discloses a metoprolol succinate sustained-release tablet and a preparation method thereof, and belongs to the field of pharmaceutical preparations, the metoprolol succinate sustained-release tablet comprises a tablet and a coating layer coated on the surface of the tablet, and the tablet is obtained by tabletting sustained-release pellets and auxiliary materials; the sustained-release pellet comprises a drug-containing pellet core and a sustained-release layer wrapping the drug-containing pellet core; the medicine-containing pill core contains a metoprolol succinate main medicine; the sustained-release layer is formed by coating the drug-containing pellet core with a sustained-release coating material; the medicine-containing pellet core is prepared by the following steps: preparing a soft material from metoprolol succinate, pellet core auxiliary materials and water by using a wet method, and then extruding, rolling and drying to obtain the medicine-containing pellet core. The sustained-release tablet adopts a multi-unit pellet sustained-release technology, so that the medicine is continuously and uniformly released within 24 hours, the blood concentration is more stable, and the heart rate and blood pressure fluctuation are reduced.

The invention belongs to the field of pharmaceutical preparations, and provides a drug sustained-release capsule for treating liver diseases as well as a preparation method and application of the drug sustained-release capsule. The sustained-release capsule provided by the invention is prepared by filling a capsule with sustained-release pellets. The drug carried by the sustained release pellet is IMM-H014 (Immunoglobulin M-H014). The sustained-release pellet is prepared by coating a sustained-release layer on a drug-loaded pellet, and the drug-loaded pellet has the characteristic of delayed release, and is stable in dissolution rate and good in bioavailability. The traditional Chinese medicine composition is used for treating non-alcoholic fatty liver, hepatitis and drug-induced liver diseases.

The invention relates to the technical field of oral sustained-release preparations, in particular to an oil-based protective hard capsule containing sustained-release pellets and a preparation method of the oil-based protective hard capsule. The preparation method comprises the following steps: firstly, preparing a capsule shell: dissolving hydroxypropyl methylcellulose, carrageenan, gellan gum and lauryl sodium sulfate in hot water in stages, aging to obtain a glue solution, dipping the glue solution, drying and cutting to obtain a primary capsule body; secondly, adding hydrophobic modified silica gel nanoparticles and a temperature response type copolymer into linseed oil to form a suspension; preparing an active drug and a sustained-release auxiliary material into a pellet core, and coating to obtain a sustained-release pellet; and finally, filling the sustained-release pellets into a capsule lower shell, filling the suspension, covering the capsule upper shell, sealing by adopting a hydroxypropyl methylcellulose solution, and heating and curing by hot air. The obtained capsule can be used for oral sustained-release medicines or functional foods after leakage detection and sterilization; liquid-solid split charging is achieved, the drug release behavior can be effectively controlled, the stability is improved, and good application prospects are achieved.

The application provides opicapone sustained-release pellets, and relates to the technical field of drug release. The opicapone sustained-release pellets comprise, from inside to outside, a drug-containing sustained-release core layer, an isolation sustained-release layer and an enteric layer in sequence. The raw materials of the drug-containing sustained-release core layer at least comprise opicapone, a sustained-release material, a filler, a binder and a pH regulator, and the sustained-release material is selected from a combination of Eudragit L, Eudragit S and a cationic polymer. Preferably, the raw materials of the isolation sustained-release layer at least comprise a combination of Eudragit L and Eudragit S. The opicapone sustained-release pellets have good stability in a gastric acid environment, can realize smooth and long-acting slow release in an intestinal environment, and improve the safety and bioavailability of the drug.

The present invention belongs to the technical field of sustained-release preparations and discloses colchicine sustained-release micropellets and their preparation method. The colchicine sustained-release micropellets comprise, from the inside out, a blank core, a colchicine drug layer, a light-shielding layer, and a sustained-release layer. The light-shielding layer includes a light-shielding agent and a suspending agent; the light-shielding agent is one or more of Fe2O3, Fe2O3·H2O, and Fe3O4. Adding iron oxide to the colchicine preparation has a more significant protective effect than titanium dioxide, unexpectedly inhibiting the photochemical degradation of colchicine and providing greater safety. The optimal effect is achieved when iron oxide is added as an independent light-shielding layer between the drug layer and the sustained-release layer.

The invention provides a budesonide enteric capsule, which is characterized in that resveratrol is used as a pellet core, budesonide, zein, hydroxypropyl methylcellulose acetate succinate, polyvinylpyrrolidone, acetyl triethyl citrate and tween-80 are used for preparing a budesonide sustained-release pellet, and the budesonide enteric capsule is prepared from the budesonide, the zein, the hydroxypropyl methylcellulose acetate succinate, the polyvinylpyrrolidone, the acetyl triethyl citrate and the tween-80. Cellulose acetate phthalate and zinc pectin are adopted to prepare the budesonide enteric-coated sustained-release pellet, and the budesonide enteric-coated capsule prepared through filling has the enteric-coated characteristic, and the effect is better than that of single use of cellulose acetate phthalate or zinc pectin as an enteric-coated material; and the budesonide enteric capsule prepared by taking resveratrol as the pellet core has better ulcerative colitis treatment effect than the budesonide enteric capsule prepared by taking cane sugar as the pellet core.

The present invention provides a sustained-release capsule of urapidil, comprising sustained-release micropellets and a hollow gelatin capsule shell; the sustained-release micropellets comprise a blank core, a drug-loading layer and a sustained-release layer, and an isolation layer is further provided between the drug-loading layer and the sustained-release layer; the drug-loading layer comprises urapidil API and a binder; the isolation layer is hydroxypropyl methylcellulose and / or hydroxypropyl cellulose; the sustained-release layer comprises a sustained-release material, an enteric material and a pore-forming agent. The urapidil sustained-release capsule of the present invention has a stable API crystal form, the prepared product has good stability, and the dissolution is stable during the accelerated test process, thus solving the problems of API crystal form transformation and low drug loading efficiency during the drug loading process of the drug-loading layer, as well as the problem of rapid dissolution during the stability test of the sustained-release capsule. The present invention also provides a method for preparing urapidil sustained-release capsules, which improves the stability of the preparation by adding an isolation layer and screening a suitable sustained-release layer prescription, thereby ensuring the safety and effectiveness of the drug.

The invention belongs to the field of medicines, and discloses a dexlansoprazole pharmaceutical composition, which comprises an enteric quick-release pellet and an enteric slow-release pellet, the enteric quick-release pellet sequentially comprises a drug application pellet, an isolation layer and an enteric quick-release layer from inside to outside, and the enteric slow-release pellet sequentially comprises the drug application pellet, the isolation layer and the enteric slow-release layer from inside to outside; the enteric coating material of the enteric quick-release pellet is selected from Eudragit L30D-55, Eudragit L30D-65, hydroxypropyl methyl cellulose phthalate or polyacrylic resin latex solution, and the enteric coating material of the enteric quick-release pellet is selected from Eudragit L30D-55, Eudragit L30D-65, hydroxypropyl methyl cellulose phthalate or polyacrylic resin latex The enteric-coated slow-release layer is made of Eudragit S100, the enteric-coated slow-release layer is prepared by taking water as a solvent, preparing the enteric-coated slow-release material into a slow-release enteric-coated layer coating solution and then adopting a fluidized bed bottom spraying coating process, and a stabilizer is added when the slow-release enteric-coated layer coating solution is prepared. No organic solvent is adopted in the preparation process, and industrial large-scale production is facilitated.

The invention relates to a preparation method of a glabrous sarcandra herb polyphenol extract and application of the glabrous sarcandra herb polyphenol extract in treatment of rheumatoid arthritis. The preparation method comprises the following steps: carrying out crushing pretreatment on a glabrous sarcandra herb raw material, sequentially extracting polyphenol components by adopting a 50-55% ethanol ultrasonic extraction process and a 65-70% ethanol acetic acid-containing microwave extraction process, and carrying out gradient purification by combining AB-8 type macroporous resin, so as to obtain the polyphenol extract with the total polyphenol content of more than or equal to 45%. The polyphenol composition mainly comprises gallic acid, quercitrin, protocatechuic acid, caffeic acid and the like, and has good antioxidant and anti-inflammatory activity. Furthermore, the invention also provides an enteric-coated sustained-release pellet preparation containing the polyphenol composition, and application of the enteric-coated sustained-release pellet preparation in treatment of rheumatoid arthritis by adjusting oxidative stress. The composition can activate an Nrf2 / HO-1 antioxidant pathway, inhibit an NF-kappa B inflammation pathway and remarkably improve the symptoms of arthritis. According to the invention, efficient utilization of natural traditional Chinese medicine resources is realized, and a safe and effective botanical drug treatment strategy is provided for rheumatoid arthritis.

The invention discloses a fidaxomicin-containing pharmaceutical composition. The pharmaceutical composition is prepared from an enteric-coated pellet and a sustained-release pellet, the mass ratio of the enteric-coated pellets to the sustained-release pellets is 3: 1; the fidaxomicin enteric-coated pellet comprises 4070% of fidaxomicin, 220% of a filling agent, 220% of a disintegrating agent, 110% of an adhesive, 0.52% of a lubricant and 410% of an enteric-coated coating material based on the mass of the enteric-coated pellet. The sustained-release pellet comprises fidaxomicin 4080%, a filler 530%, a disintegrating agent 520%, an adhesive 110%, a lubricant 0.52% and a sustained-release coating material 410% based on the mass of the sustained-release pellet. The fidaxomicin pharmaceutical composition provided by the invention can effectively avoid degradation consumption of fidaxomicin under the action of gastric acid, and can maintain relatively long treatment concentration and longer action time after reaching the intestinal tract, so that the medicine taking frequency is reduced, the effectiveness and safety of medicine use are ensured, the sterilization effect is maximized, and the curative effect of the fidaxomicin is improved. Various gastrointestinal tract side effects are obviously reduced.

This invention proposes a compound ambroxol sustained-release microsphere and its preparation method. The compound ambroxol sustained-release microsphere comprises ambroxol hydrochloride, clenbuterol hydrochloride, and a cellulose ester sustained-release material, effectively controlling the dissolution differences between ambroxol hydrochloride and clenbuterol hydrochloride, enabling simultaneous and stable release of both drugs and avoiding efficacy fluctuations due to different release rates. Furthermore, the microsphere utilizes a hot-melt extrusion process, ensuring uniform dispersion of the two active pharmaceutical ingredients within the sustained-release material, thus resolving the uniformity issue caused by low clenbuterol hydrochloride content. The preparation process requires no organic solvents, eliminating solvent residues and preventing degradation or reactions of the active pharmaceutical ingredients in solvents, thereby improving product stability.

The invention relates to the technical field of pharmaceutical preparations, in particular to a Tibetan medicine fermentation extract sustained-release pellet preparation and a preparation method thereof. The traditional Chinese medicine composition is prepared from 25-35 parts of herba taxilli extract, 2-4 parts of citric acid, 8-12 parts of sodium alginate, 5-8 parts of hydroxypropyl methylcellulose, 6-10 parts of ethyl cellulose and 2-3 parts of talcum powder. According to the Tibetan medicine fermentation extract sustained-release pellet preparation and the preparation method thereof, through extraction of a Zhaxun fermentation product, a complex matrix structure formed by microbial metabolism can be fully destroyed, the dissolution and release efficiency of active ingredients is improved, and the loss of effective substances in the extraction process is reduced; meanwhile, the mixing amount of impurity components in the extract is reduced, the material flowability and uniformity during pellet forming are improved, the compatibility of the extract and a sustained-release carrier is enhanced, the drug release rate of the pellet in the body is more stable, the long-acting drug release effect is achieved, and the clinical medication effectiveness and safety of the sustained-release pellet are improved.

The invention discloses a preparation method of diclofenac sodium delayed sustained-release tablets, which comprises the following steps: S1, uniformly mixing diclofenac sodium, a waxy sustained-release material and a high-molecular retardant material, then transferring the mixture into a melting spheronization pelleting machine, heating and stirring, extruding the mixture into strips through a screw extruder, and then preparing sustained-release pellets on a spheronization machine; s2, preparing a suspension solution from an enteric material, a plasticizing material, a lubricating material and a solvent, transferring the sustained-release pellets into a fluidized bed, atomizing the suspension solution, spraying the atomized suspension solution on the surfaces of the sustained-release pellets, and heating, ventilating and drying to obtain enteric sustained-release pellets; and S3, uniformly stirring and mixing the enteric-coated sustained-release pellets, a filling agent, a flow aid and a lubricating agent, and pressing on a tablet press to obtain the diclofenac sodium delayed sustained-release tablet. The medicine can be prevented from being released in the stomach, the problem of irritation to the stomach is avoided, the safety of the medicine in the aspect of gastrointestinal tracts is greatly improved, and the medicine is more suitable for being taken by patients with gastric diseases.

The invention discloses a lisinopril amlodipine compound sustained-release tablet and a preparation method thereof, the compound sustained-release tablet comprises a sustained-release part and a quick-release part, the sustained-release part is a sustained-release pellet and comprises lisinopril, amlodipine besylate, a sustained-release substrate ethyl cellulose, hydroxypropyl methylcellulose and talcum powder, and the quick-release part is a sustained-release pellet and comprises a sustained-release part and a quick-release part. The quick release part comprises lisinopril, amlodipine, microcrystalline cellulose and carboxymethyl starch sodium. The compound sustained release tablet can maintain drug sustained release within 24 hours, and the phenomenon of large peak valley is avoided, so that stable pressure reduction during administration is realized.

The invention provides an escomeprazole magnesium capsule preparation which is composed of a normal-release pellet and a sustained-release pellet, compared with a reference preparation 'NEXIUM', the escomeprazole magnesium capsule preparation has the effect taking speed close to that of the reference preparation and can maintain the effect taking time of 1-2 days, the drug administration frequency can be reduced, and the bioavailability of the escomeprazole magnesium capsule preparation is improved. The selectivity is increased for some patients who cannot take medicine every day, cannot be administrated in time or are inconvenient to take medicine for multiple times every day.